JP2025508066A - 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 - Google Patents

目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 Download PDF

Info

Publication number
JP2025508066A
JP2025508066A JP2024553409A JP2024553409A JP2025508066A JP 2025508066 A JP2025508066 A JP 2025508066A JP 2024553409 A JP2024553409 A JP 2024553409A JP 2024553409 A JP2024553409 A JP 2024553409A JP 2025508066 A JP2025508066 A JP 2025508066A
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
light chain
variable region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024553409A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508066A5 (https=
Inventor
サラ マジョッキ
クシシュトフ マステルナク
リミン シャン
ニコラス フィッシャー
グザヴィエ ショーシェ
Original Assignee
ノビミューン エスアー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノビミューン エスアー filed Critical ノビミューン エスアー
Publication of JP2025508066A publication Critical patent/JP2025508066A/ja
Publication of JP2025508066A5 publication Critical patent/JP2025508066A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2024553409A 2022-03-07 2023-03-07 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体 Pending JP2025508066A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263317491P 2022-03-07 2022-03-07
US63/317,491 2022-03-07
US202263323893P 2022-03-25 2022-03-25
US63/323,893 2022-03-25
PCT/IB2023/000124 WO2023170474A1 (en) 2022-03-07 2023-03-07 Cd28 bispecific antibodies for targeted t cell activation

Publications (2)

Publication Number Publication Date
JP2025508066A true JP2025508066A (ja) 2025-03-21
JP2025508066A5 JP2025508066A5 (https=) 2026-03-17

Family

ID=86272440

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024553409A Pending JP2025508066A (ja) 2022-03-07 2023-03-07 目的としたｔ細胞活性化のためのｃｄ２８二重特異性抗体

Country Status (8)

Country Link
US (1) US20240002544A1 (https=)
EP (1) EP4490192A1 (https=)
JP (1) JP2025508066A (https=)
CN (1) CN119233993A (https=)
AU (1) AU2023232992A1 (https=)
CA (1) CA3249273A1 (https=)
IL (1) IL314916A (https=)
WO (1) WO2023170474A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL305828A (en) * 2021-03-22 2023-11-01 Novimmune Sa Bispecific antibodies targeting CD47 and PD-L1 and methods of using them
EP4493592A1 (en) 2022-03-14 2025-01-22 LamKap Bio gamma AG Bispecific gpc3xcd28 and gpc3xcd3 antibodies and their combination for targeted killing of gpc3 positive malignant cells
US20240254234A1 (en) 2022-10-21 2024-08-01 Novimmune Sa PD-L1xCD28 BISPECIFIC ANTIBODIES FOR IMMUNE CHECKPOINT-DEPENDENT T CELL ACTIVATION
WO2025051895A1 (en) * 2023-09-06 2025-03-13 Novimmune Sa Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activity
TW202544034A (zh) * 2024-05-06 2025-11-16 美商榮都醫療公司 結合至ｃｄ２８及ｎｅｃｔｉｎ－４之雙特異性抗體
WO2026078067A1 (en) 2024-10-08 2026-04-16 Novimmune Sa Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
WO2006028936A2 (en) 2004-09-02 2006-03-16 Genentech, Inc. Heteromultimeric molecules
PT2171060E (pt) 2004-11-11 2013-11-18 Theramab Llc Anticorpo anti-cd28 superagonista
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
DE102005028778A1 (de) 2005-06-22 2006-12-28 SUNJÜT Deutschland GmbH Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage
JP2009541275A (ja) 2006-06-22 2009-11-26 ノボ・ノルデイスク・エー／エス 二重特異性抗体の生産
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
CN103261220B (zh) 2010-08-16 2016-06-15 诺夫免疫股份有限公司 用于生成多特异性和多价抗体的方法
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
PE20141017A1 (es) 2011-03-02 2014-08-25 Roche Glycart Ag Anticuerpos del cea
BR112014010580B1 (pt) 2011-11-04 2021-01-12 Zymeworks, Inc. constructo de fc heteromultimérico isolado, composição, uso de um constructo de fc heteromultimérico isolado, composição de ácido nucléico e método para expressar o constructo de fc heteromultimérico isolado
LT2961771T (lt) 2013-02-26 2020-03-10 Roche Glycart Ag Bispecifinės t ląstelę aktyvinančios antigeną surišančios molekulės, specifinės cd3 ir cea antigenams
WO2016036678A1 (en) 2014-09-02 2016-03-10 Medimmune, Llc Formulations of bispecific antibodies
WO2018209304A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Msln targeting trispecific proteins and methods of use
US11260117B2 (en) * 2017-05-26 2022-03-01 Novimmune Sa Anti-CD47 x anti-mesothelin antibodies and methods of use thereof
AU2018303254B2 (en) * 2017-07-21 2025-05-29 Novimmune Sa Generating multispecific antibody mixtures and methods of uses thereof
EP3802599B1 (en) * 2018-06-03 2023-12-20 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
IL279354B1 (en) 2018-06-21 2026-02-01 Regeneron Pharma Bispecific antibodies against psma and against cd28 and their uses
US11453721B2 (en) 2018-12-19 2022-09-27 Regeneran Pharmaceuticals, Inc. Bispecific anti-MUC16 x anti-CD28 antibodies and uses thereof
MA54540A (fr) 2018-12-19 2021-10-27 Regeneron Pharma Anticorps anti-cd28 x anti-cd22 bispécifiques et leurs utilisations
WO2020127628A1 (en) 2018-12-21 2020-06-25 F. Hoffmann-La Roche Ag Tumor-targeted superagonistic cd28 antigen binding molecules
UA128001C2 (uk) 2018-12-21 2024-03-06 Ф. Хоффманн-Ля Рош Аг Націлені на пухлину агоністичні cd28-антигензв'язувальні молекули
CA3134335A1 (en) 2019-03-22 2020-10-01 Regeneron Pharmaceuticals, Inc. Egfr x cd28 multispecific antibodies
WO2021053587A1 (en) 2019-09-18 2021-03-25 Klaus Strein Bispecific antibodies against ceacam5 and cd3
EP3831849A1 (en) 2019-12-02 2021-06-09 LamKap Bio beta AG Bispecific antibodies against ceacam5 and cd47
JP7789002B2 (ja) 2020-01-29 2025-12-19 インヒブルクス バイオサイエンシズ インコーポレイテッド Ｃｄ２８シングルドメイン抗体ならびにその多価および多重特異性の構築物
AU2021295549A1 (en) 2020-06-23 2022-11-24 F. Hoffmann-La Roche Ag Agonistic CD28 antigen binding molecules targeting Her2
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
HRP20240213T1 (hr) * 2020-12-18 2024-04-26 Lamkap Bio Beta Ag Bispecifična antitijela protiv ceacam5 i cd47

Also Published As

Publication number Publication date
AU2023232992A1 (en) 2024-08-15
CN119233993A (zh) 2024-12-31
US20240002544A1 (en) 2024-01-04
CA3249273A1 (en) 2023-09-14
IL314916A (en) 2024-10-01
EP4490192A1 (en) 2025-01-15
WO2023170474A1 (en) 2023-09-14

Similar Documents

Publication Publication Date Title
EP3882275B1 (en) Anti-pd-1 and anti-vegfa bifunctional antibody, pharmaceutical composition thereof and use thereof
AU2019264965B2 (en) Antibodies specific to human Nectin4
JP7844558B2 (ja) リンパ球における阻害経路の中和
JP7425604B2 (ja) 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用
KR102937285B1 (ko) 신규 항-pd-l1 항체
US20240002544A1 (en) Cd28 bispecific antibodies for targeted t cell activation
JP7701911B2 (ja) Ｃｅａｃａｍ５およびｃｄ３に対する二特異性抗体
WO2022256563A1 (en) Anti-ccr8 antibodies and uses thereof
JP2017520575A (ja) 二重特異的ヘテロ二量体ダイアボディおよびその使用
JP2025508118A (ja) 新規免疫調節剤の開発および使用
KR20200092301A (ko) 다중-특이적 항체 및 이를 제조하는 방법 및 이의 용도
JP2023532807A (ja) Ｐｓｍａ及びガンマ－デルタｔ細胞受容体に結合する抗体
CN113164777A (zh) Csf1r/ccr2多特异性抗体
JP2025503109A (ja) サイトカインシグナル伝達経路の選択的な活性化のための組成物および方法
US12122850B2 (en) Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells
KR20220144821A (ko) Cd137 결합 분자 및 그것의 용도
CN114539420B (zh) 抗b7-h3单克隆抗体、抗b7-h3×cd3双特异性抗体、制备方法及其应用
EP4663660A1 (en) Trispecific antigen-binding molecule and use thereof
WO2026078067A1 (en) Fcrh5 monospecific antibodies and derived fcrh5xcd28 bispecific antibodies and use thereof
WO2023199927A1 (ja) がん治療におけるｐｄ－１シグナル阻害剤との組み合わせによる抗ｔｓｐａｎ８－抗ｃｄ３二重特異性抗体の使用
HK40101629A (zh) 包含抗cldn18.2抗体的双特异性抗体、药物组合物及用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260309

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260309